The ratings of 7 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This is a rough week for Johnson & Johnson (JNJ). The company’s rating falls to D from the previous week’s C. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
This week, SCYNEXIS, Inc.’s (SCYX) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SCYX stock.
Cipher Pharmaceuticals Inc.’s (CPHR) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in operating margin growth and earnings growth. For more information, get Portfolio Grader’s complete analysis of CPHR stock.
Evoke Pharma, Inc. (EVOK) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EVOK stock.
This week, Repros Therapeutics Inc. (RPRX) drops from a C to a D rating. Repros Therapeutics Inc. is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Oculus Innovative Sciences, Inc. (OCLS) gets weaker ratings this week as last week’s C drops to a D. Oculus Innovative Sciences, Inc. develops and manufactures products to prevent and eliminate infections in chronic and acute wounds. The company also gets F’s in operating margin growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCLS stock.
Alexza Pharmaceuticals, Inc. (ALXA) earns a D this week, moving down from last week’s grade of C. Alexza Pharmaceuticals, Inc. engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of ALXA stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
